Asset

ANAGRELIDE HYDROCHLORIDE

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01214915phase3completed2010-10-272012-10-24ShireEffect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
NCT00413634phase2completed2006-11-132008-01-22ShireThe Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

FDA applications (1)

ApplicationTypeApplicant
NDA 020333NDATAKEDA PHARMACEUTICALS USA INC

Marketed products (2)

  • AGRYLIN
  • AGRYLIN